Risks

Long inventory cycles and a 84.6-day cash conversion cycle can pressure working capital and limit growth flexibility versus faster-turning medtech peers.

Interest coverage is reported at zero, so any demand softness or margin compression could constrain financing capacity more than for better-covered peers.

A 50.2-day receivables cycle increases exposure to customer payment timing, which can weigh on cash realization relative to peers with tighter collections.

Moderate leverage with net debt to EBITDA near 0.4x reduces immediate balance-sheet stress, but it still leaves less cushion than net-cash peers if execution weakens.

Opportunities

Current ratio of 1.82 and quick ratio of 1.08 provide liquidity headroom, supporting operating continuity better than more stretched peers.

Net debt to EBITDA near 0.4x leaves capacity to fund commercialization or product expansion, giving more flexibility than highly levered peers.

Payables days of 73.8 partly offset inventory investment, which can support cash preservation versus peers with weaker supplier terms.

If demand remains stable, working-capital normalization could release cash and improve free-cash-flow conversion faster than peers with structurally longer cycles.

Overall Score

IRIX shows manageable liquidity and modest leverage, but long working-capital cycles and weak interest coverage create meaningful downside versus better-capitalized peers, while cash headroom and balance-sheet flexibility provide some upside.